Close Menu

Christopher Hall, John W. Hanna

Feb 28, 2017

Veracyte named Christopher Hall as its president and promoted John W. Hanna  to chief commercial officer. Hall succeeds Bonnie Anderson as president and continues as the company's chief operating officer, a role he's had since 2014. He joined Veracyte in 2010 as chief commercial officer. Anderson remains CEO of Veracyte and chairman of its board. Hanna joined Veracyte in 2011 and was previously its vice president of marketing.  

More Like This

Jun 14, 2019

Leena Das-Young

Guardant health said that Leena Das-Young is leaving her position as chief LUNAR officer and general manager at the company for personal reasons. She will continue her service with the firm through June 18, 2019. In connection with her departure, and in exchange for a customary release of claims, Das-Young will be entitled to certain benefits under the company’s executive severance plan, as well as the retention of certain relocation benefits previously provided to her.

Jun 11, 2019

Thomas Schinecker, Barbara Schädler, Michael Heuer, Stephan Feldhaus, Peter Voser

Thomas Schinecker has been appointed as CEO of Roche Diagnostics and a member of the firm's corporate executive committee, effective August 1. He will succeed Michael Heuer, who is retiring at the end of July. Schinecker is currently head of Centralized and Point of Care Solutions at Roche Diagnostics. Previously, he was general manager for Roche Diagnostics Germany, and before that, he held various management positions in marketing and sales as well as product development at Roche Diagnostics. He holds a PhD in molecular biology from New York University.

Barbara Schädler will become head of group communications and a member of Roche's enlarged Corporate Executive Committee, effective October 1. She will succeed Stephan Feldhaus, who will leave Roche at the end of September. Schädler is currently head of communications and public affairs at E.ON. Previously, she held communications manager positions at Lufthansa, SAP, and the German Federal Ministry of Finance. She holds a master's degree in economics from the University of Mainz.

Peter Voser will step down from the board of directors of Roche at the end of June due to his additional role as interim CEO of ABB.

Jun 11, 2019

Gail Marcus

Binx Health has appointed Gail Marcus to its board of directors. Marcus has held executive positions in a number of healthcare sectors, including services, diagnostics, healthcare provision, and managed care. She held leadership positions at United Healthcare, Cigna, and private equity-backed diagnostic organizations; has an academic appointment at Massachusetts College of Pharmacy and Health Sciences; and serves on the boards of Natera, Cambridge Epigenetix, and Triple S Management, a Blue Cross Blue Shield affiliate in Puerto Rico.

Jun 10, 2019

George Goedesky

George Goedesky has joined Affinity Biosensors as vice president of sales of marketing. He will lead the rollout of the LifeScale AST system for rapid antibiotic susceptibility tests. Most recently, Goedesky led the adoption of the Burker MALDII Biotyper platform in the Americas. The LifeScale AST platform is currently in US clinical trials for identifying targeted therapy for sepsis, Affinity Biosensors said. 

Jun 06, 2019

Eric d'Esparbes

Progenity has hired Eric d'Esparbes as its senior VP and CFO. Prior to Progenity, d'Esparbes served as CFO and interim principal executive officer at Innoviva. Before Innoviva, he held roles as CFO at Joule Unlimited, VP of finance at AEI, and CFO for Meiya Power Company. 

Jun 05, 2019

David King, Adam Schechter

David King is retiring from Laboratory Corporation of America as its president and CEO on Oct. 31 and will become its executive chairman of the board, effective Nov. 1, the company said this week. Adam Schechter will succeed King as president and CEO on that day.

King became CEO of LabCorp on Jan. 1, 2007. Prior to that he was the firm's executive vice president and COO, as well as its executive VP of strategic planning and corporate development. He joined the company as senior VP, general counsel, and chief compliance officer in 2001, and was LabCorp's principal outside legal counsel for several years before that.

The company noted that it has tripled in sized under King's leadership. It does business in more than 100 countries now, employs almost 61,000 employees, and recorded revenue of more than $11 billion in 2018.

Schechter is currently the lead independent director of LabCorp's board, which expects to choose another board member to be the lead independent director at a later date. Schechter, who has been a LabCorp director for six years, was formerly Merck executive vice president and president of global human health.

Jun 04, 2019

Michael Lee Astion, Sterling Bennett, and Others

The Project Santa Fe Foundation has expanded its board of directors. The new board members are Michael Lee Astion, a professor and medical director in the department of laboratories at Seattle Children's Hospital; Sterling Bennett, adjunct associate professor in the department of pathology at the University of Utah School of Medicine, and medical director at Intermountain Healthcare central laboratory; and Mark Fung, a professor and vice chair for population health in the department of pathology and laboratory medicine at the Robert Larner M.D. College of Medicine at the University of Vermont.

Also named to the board were Curtis Hanson, a professor and vice chair, extramural laboratory affairs, department of laboratory medicine and pathology at Mayo Clinic, and chief medical officer at Mayo Clinic Laboratories; and Karen Kaul, the Duckworth Family Chair of Molecular Pathology, chair of pathology and laboratory medicine at NorthShore University HealthSystem, and clinical professor of pathology at the University of Chicago Pritzker School of Medicine.

May 30, 2019

Frank Ong

Frank Ong has joined EverlyWell, a home-based testing firm, as its chief medical and chief scientific officer. Ong previously held leadership positions at Guardant Health, Roche Diagnostics, and Illumina. Last month, the Austin, Texas-based firm said that it raised $50 million in private financing. 

May 30, 2019

Padma Sundar, Kim Dickinson

OncoCyte has appointed Padma Sundar as its senior VP of marketing and market access. The firm has also appointed Kim Dickinson as its VP of clinical operations.

Prior to OncoCyte, Sundar served as VP of strategy and market access at CellMax Life. Before CellMax, she acted as director of marketing at Guardant Health. Prior to Guardant, Sundar served as senior director at Roche Sequencing. She also held the role of senior director for Affymetrix's oncology portfolio.

Before OncoCyte, Dickinson served as VP of research and development and chief pathologist at Biocare Medical. Prior to BioCare, she served as VP of clinical operations at Roche Tissue Diagnostics. She also served as medical director for Laboratory Corporation of America' clinical trials division. Before working at LabCorp, Dickinson acted as medical director at Esoteric Testing. Prior to Esoteric, Dickinson worked at Quest Diagnostics, Citrus Valley Medical Center, and Pioneer Hospital.

May 29, 2019

Steven Kafka

ArcherDx has appointed Steven Kafka as executive chairman of its board of directors. Kafka will replace Kyle Lefkoff, founder and general partner of Boulder Ventures. Lefkoff will remain on the board of ArcherDx. Kafka currently serves as a partner at Third Rock Ventures. Prior to Third Rock Ventures, Kafka served as president and chief operating officer at Foundation Medicine. Prior to Foundation, Kafka held executive roles at several public and private oncology drug discovery and development companies.

May 23, 2019

Douglas Clark

TriCore Reference Laboratories has named Douglas Clark chief medical officer, effective September 2019. Clark is already serving as chairman of TriCore's board of directors. He most recently served as pathology department chairman and professor at the University of New Mexico. Prior to that, he served as director of the division of cytopathology at The Johns Hopkins Medical Institutions. 

May 21, 2019

Sangeeta Bhorade

Veracyte has hired Sangeeta Bhorade as medical director of pulmonology to lead medical affairs for the firm's pulmonology products. Bhorade joins Veracyte from Northwestern University Feinberg School of Medicine, where she served as professor of medicine and medical director of the lung transplant program. Prior to Northwestern, Bhorade served as medical director of the lung transplant program at the University of Chicago Medical Center. She has also served as associate medical director of lung transplant at Loyola University Chicago.

May 09, 2019

Sun Kim

Centogene has appointed Sun Kim as its chief strategy and investor relations officer. Prior to Centogene, Kim served as head of corporate strategy at Shire Pharmaceuticals. Before Shire, Kim worked at Alcon for six years, where he served in multiple roles including head of strategy and general manager of Alcon Singapore.

May 07, 2019

David Parker, Mike Evans

David Parker, a general partner in Ampersand Capital Partners, and Mike Evans, operating partner at Ampersand, have joined the board of Dutch firm Genome Diagnostics, which said this week that Ampersand invested an undisclosed amount in the firm. Ampersand, as a result, became minority shareholders in GenDx. 

Apr 30, 2019

Jimmy Lin

Freenome has appointed Cheng-Ho Jimmy Lin, as its chief scientific officer, with responsibilities for scientific strategy, research operations, and growing the company’s scientific team. Prior to joining the private sector, Lin led the intramural clinical genomics program at the National Cancer Institute at the National Institutes of Health. At Johns Hopkins and Washington University in St Louis, he also spearheaded the computational analyses of exome sequencing studies in multiple cancer types.

Lin's most recent role was CSO for oncology at Natera, where he drove the development and launch of that firm's blood-based assays for cancer monitoring residual disease detection. He holds an MD and PhD in cellular and molecular medicine and a Masters in health sciences in bioinformatics from Johns Hopkins School of Medicine.